INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.GeronGERN (market cap $0.493B)Geron is a leading edge biotech company focusing (and please excuse the spelling) on stem cells, nuclear cell transfer, telomorase, etc. Basically, they hope to be able to regrow cells to regenerate organs and nerves; and to control cell life and death via telomorase, thereby controlling cancer and possibly prolonging life. They have begun clinical trials and have been delayed by a very cautious FDA.Geron and GERN continue to be highly speculative in many ways: company, technology, treatment and stock. This will change with progress through the clinical trials, which will take a few more years. That's an improvement because years ago the wait was several years.I continue to HOLD, and would consider buying more if cash were available and if clinical trials showed dramatic results. Dramatic results are possible considering the impact of accident victims walking again, or cancer patients finding their tumors have shrunk. I don't know if such results are probable, but they do seem possible.DISCLOSURE LTBH since 1999.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat